{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:10:02Z","timestamp":1758964202376,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clinthera.2020.05.009","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T02:22:16Z","timestamp":1593570136000},"page":"1317-1329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Thorough QT Study of the Combination Glecaprevir\u00a0+ Pibrentasvir on Cardiac Repolarization in Healthy Subjects"],"prefix":"10.1016","volume":"42","author":[{"given":"Rajneet K.","family":"Oberoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-8181","authenticated-orcid":false,"given":"Weihan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rosebraugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.05.009_bib1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2005.02429.x","article-title":"Polypharmacy and Crohn's disease","volume":"21","author":"Cross","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"year":"2018","series-title":"Maviret [summary of Product Characteristics]","key":"10.1016\/j.clinthera.2020.05.009_bib2"},{"key":"10.1016\/j.clinthera.2020.05.009_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2020.05.009_bib4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.009_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.009_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol : Off Clin Prac J Am Gastroenterol Ass"},{"key":"10.1016\/j.clinthera.2020.05.009_bib7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis : Off Publ Inf Dis Socie Am"},{"key":"10.1016\/j.clinthera.2020.05.009_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2020.05.009_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2020.05.009_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinthera.2020.05.009_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir: integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2020.05.009_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1011909827909","article-title":"Polypharmacy among patients admitted to hospital with rheumatic diseases","volume":"23","author":"Viktil","year":"2001","journal-title":"Pharm World Sci : PWS"},{"issue":"9460","key":"10.1016\/j.clinthera.2020.05.009_bib13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)17950-1","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2020.05.009_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.009_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.xphs.2016.10.007","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study","volume":"106","author":"Lin","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.clinthera.2020.05.009_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.350","article-title":"Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study","volume":"7","author":"Lin","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2020.05.009_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13318-017-0428-8","article-title":"Pharmacokinetic interactions and safety of coadministration of glecaprevir and pibrentasvir in healthy volunteers","volume":"43","author":"Lin","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.05.009_bib18","first-page":"1116","article-title":"Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis","volume":"159","author":"Gerdes","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2020.05.009_bib19","first-page":"2002","article-title":"(Abbott Biosignal System): a workbench system software for data mining in biosignals, with applications in drug research and development","volume":"22\u201325 Sept","author":"Safer","year":"2002","journal-title":"Comput Cardiol"},{"year":"2010","series-title":"GUIDANCE DOCUMENT: Guide for the Analysis and Review of QT\/QTc Interval Data","author":"Canada","key":"10.1016\/j.clinthera.2020.05.009_bib20"},{"key":"10.1016\/j.clinthera.2020.05.009_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0091270007307881","article-title":"Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review","volume":"48","author":"Garnett","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.05.009_bib22","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/jcph.959","article-title":"Pharmacokinetics, safety, and tolerability of glecaprevir and pibrentasvir in healthy white, Chinese, and Japanese adult subjects","volume":"57","author":"Lin","year":"2017","journal-title":"J\u00a0Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:39Z","timestamp":1758963219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0149291820302435"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Thorough QT Study of the Combination Glecaprevir\u00a0+ Pibrentasvir on Cardiac Repolarization in Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}